$3,750,000,000 National Settlement Fen-Phen Diet Injuries Awarded
In September 1997, Fen Phen was withdrawn from the market. The combination of fenfluramine and dexfenfluramine was leading to heart valve injuries that were affecting a high percentage of Fen Phen takers. American Home Products, the drug’s manufacturer, was accused of withholding information that would have warned Fen Phen users of the risks involved so they could continue to sell the popular diet drug. The FDA issued thousands of warning letters informing patients and doctors of possible valvular heart disease in July of 1997, and in September 1997 is when the FDA requested a voluntary withdrawal of Fen Phen by the drug company. Following the initial medical warning reports that linked Fen Phen to serious forms of valvular heart disease, various class actions were filed against American Home Products. After Fen Phen was withdrawn from the market, a nationwide settlement began negotiations. As of January 11, 2002 the Fen Phen Settlement became final. Barry Eichen, Esq. of Eichen Crutchlow Zaslow, LLP sat on the New Jersey Fen-Phen Steering Committee which assisted in the National Settlement for $3.75 billion.